Author/Authors :
Di Benedetto, Paolo Clinic of Orthopaedics - Academic Hospital of Udine, Italy , Zangari, Andrea Clinic of Orthopaedics - Academic Hospital of Udine, Italy , De Franceschi, Dania Clinic of Orthopaedics - Academic Hospital of Udine, Italy , Daniele Di Benedetto, Enrico Clinic of Orthopaedics - Academic Hospital of Udine, Italy , Cainero, Vanni Clinic of Orthopaedics - Academic Hospital of Udine, Italy , Beltrame, Alessandro Clinic of Orthopaedics - Academic Hospital of Udine, Italy , Gisonni, Renato Clinic of Orthopaedics - Academic Hospital of Udine, Italy , Causero, Araldo Clinic of Orthopaedics - Academic Hospital of Udine, Italy
Abstract :
Background and aim of the work: Periprostethic joint infection (PJI) is a severe post-operative com-plication after Primary Total Hip Arthroplasty (THA). According to the classification of PJI early acute PJI occurs within 4 weeks from surgery. Some authors think that Rivaroxaban is a risk factor in the incidence of early acute PJI. We analyze our experience about this item. Materials and methods: We analyze our experience from 1st January 2015 to 31th December 2016. We consider all consecutive hip arthroplasty implants in this period. Results: In the 205 patients analysed we not find early acute PJI in Rivaroxaban group nor in the others assuming another kind of thromboprophylaxis. Conclusions: In our series there is no evidence of association between Rivaroxaban and early acute PJI. This is a retrospective cohort study, so we need more studies and more robust experimental designs to confirm these results. (www.actabiomedica.it)
